Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
|Videos|July 28, 2022
Dr. Staehler on novel PET imaging agent for kidney cancer
Author(s)Urology Times staff
Advertisement
In this video, Michael Staehler, MD, a professor of Urology at the University of Munich, discusses early results with 68GA-EMP-100 PET, a novel agent for imaging c-MET expression in renal cell carcinoma. Staehler presented that abstract, “First in-human results of 68GA-EMP-100 PET for imaging c-MET expression in renal cell carcinoma,” at the 2022 AUA annual meeting (abstract
Advertisement
Related to this article
The target enrollment goal has been reached in the phase 3 BiPASS study, evaluating PSMA-PET plus MRI for prostate cancer detection.
Advertisement
Advertisement
Trending on Urology Times
1
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
2
FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity
3
Topical sildenafil cream associated with lower systemic exposure vs oral sildenafil
4
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
5